NCT01256658

A Community Setting Study of Malaria After Systematic Treatment of Symptomatic Carriers of P. Falciparum With COA566 (Coartem®)

A Cluster Randomized, Single-centre, Controlled, Parallel,12-month Prospective Study and Additional 12-month Follow-up in Africa of Malaria Incidence in a Community Setting Following Systematic Treatment of P. Falciparum Asymptomatic Carriers With Artemether-lumefantrine (Coartem® / Coartem® Dispersible)

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 14,075 (actual)
• Sponsor: Novartis · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

This study assessed the impact of the systematic detection by Rapid Diagnostic Test (RDT) and treatment of asymptomatic carriers of malaria parasites (P. falciparum) with COA566 on a number of clinical malaria cases in children less than 5 years of age and the improvement of hemoglobin levels in the overall population.

Conditions

• Malaria

Interventions

Type	Name	Description
DRUG	COA566	COA566 tablets or dispersible tablets twice daily during 3 days; dosage according to body weight.

Timeline

• Start date: 2010-11-01
• Primary completion: 2012-07-01
• Completion: 2012-07-01
• First posted: 2010-12-08
• Last updated: 2014-02-10
• Results posted: 2013-11-25

Locations

3 sites across 1 country: Burkina Faso